Skip to main content
SpringerLink
Log in

Contraception for Women Living with HIV

  • Chapter
  • First Online:
Contraception for the Medically Challenging Patient

  • 988 Accesses

Abstract

For women living with HIV, there are several issues to consider in attending to their reproductive health and contraceptive needs. In this chapter we review common medical comorbidities, pregnancy-associated risks, and reproductive health concerns that present among HIV-infected women. Although most contraceptive methods are safe for women with HIV, careful consideration of other comorbidities and current medications are important in helping the individual select an ideal contraceptive option. While controversies exist regarding the potential for certain hormonal contraceptives to contribute to increased HIV transmission and progression, the current research is inconclusive and does not influence current contraceptive recommendations. As several antiretroviral drugs may interact with hormonal contraceptives to reduce effectiveness, careful patient counseling during method selection and encouragement of dual protection with condoms are important.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Centers for Disease Control and Prevention (CDC). Pneumocystis pneumonia – Los Angeles. MMWR. 1981;30:250–2.

    Google Scholar 

  2. Ribeiro PS, Jacobsen KH, Mathers CD, Garcia-Moreno C. Priorities for women's health from the Global Burden of Disease study. Int J Gynaecol Obstet. 2008;102(1):82–90. Epub 2008/04/05.

    PubMed  Google Scholar 

  3. World Health Organization. Women and health: today's evidence, tomorrow's agenda. Geneva: World Health Organization; 2009.

    Google Scholar 

  4. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global report: UNAIDS report on the global AIDS epidemic; 2013.

    Google Scholar 

  5. Centers for Disease Control and Prevention (CDC). Monitoring selected national HIV prevention and care objectives by using HIV surveillance data – United States and 6 U.S. dependent areas – 2010. HIV Surveill Suppl Rep. 2012;17(3). Epub Jun 2012.

    Google Scholar 

  6. Centers for Disease Control and Prevention (CDC). Estimated HIV incidence among adults and adolescents in the United States, 2007–2010. HIV Surveill Suppl Rep. 2012;17(4). Epub Dec 2012.

    Google Scholar 

  7. Centers for Disease Control and Prevention (CDC). Estimated HIV incidence among adults and adolescents in the United States, 2007–2010. HIV Surveill Suppl Rep. 2012;17(4).

    Google Scholar 

  8. Centers for Disease Control and Prevention (CDC). Recommendations for assisting in the prevention of perinatal transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus and acquired immunodeficiency syndrome. MMWR. 1985;34(48):721–6. 31–2. Epub 1985/12/06.

    Google Scholar 

  9. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74. Epub 2010/07/21.

    CAS  PubMed Central  PubMed  Google Scholar 

  10. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505. Epub 2011/07/20.

    CAS  PubMed Central  PubMed  Google Scholar 

  11. Reynolds SJ, Makumbi F, Nakigozi G, Kagaayi J, Gray RH, Wawer M, et al. HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. AIDS. 2011;25(4):473–7. Epub 2010/12/17.

    CAS  PubMed Central  PubMed  Google Scholar 

  12. Cunningham WE, Andersen RM, Katz MH, Stein MD, Turner BJ, Crystal S, et al. The impact of competing subsistence needs and barriers on access to medical care for persons with human immunodeficiency virus receiving care in the United States. Med Care. 1999;37(12):1270–81. Epub 1999/12/22.

    CAS  PubMed  Google Scholar 

  13. Fleishman JA, Gebo KA, Reilly ED, Conviser R, Christopher Mathews W, Todd Korthuis P, et al. Hospital and outpatient health services utilization among HIV-infected adults in care 2000–2002. Med Care. 2005;43(9 Suppl):III40–52. Epub 2005/08/24.

    PubMed  Google Scholar 

  14. Ribaudo H, Smith K, Robbins G, Flexner C, Haubrich R, Chen Y, et al. Race differences in the efficacy of initial ART on HIV infection in randomized trials undertaken by ACTG. 18th Conference on retroviruses and opportunistic infections, Boston, MA, 27 Feb to 2 Mar 2011.

    Google Scholar 

  15. Murphy DA, Greenwell L, Hoffman D. Factors associated with antiretroviral adherence among HIV-infected women with children. Women Health. 2002;36(1):97–111. Epub 2002/09/07.

    PubMed  Google Scholar 

  16. Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM, Lambert PC, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA. 2008;300(1):51–9. Epub 2008/07/03.

    CAS  PubMed  Google Scholar 

  17. Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166(15):1632–41. Epub 2006/08/16.

    PubMed  Google Scholar 

  18. Currier JS, Taylor A, Boyd F, Dezii CM, Kawabata H, Burtcel B, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr. 2003;33(4):506–12. Epub 2003/07/19.

    PubMed  Google Scholar 

  19. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, et al. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS. 2010;24(8):1228–30. Epub 2010/04/20.

    PubMed  Google Scholar 

  20. Klein D, Hurley LB, Quesenberry Jr CP, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr. 2002;30(5):471–7. Epub 2002/08/03.

    CAS  PubMed  Google Scholar 

  21. Triant VA. HIV infection and coronary heart disease: an intersection of epidemics. J Infect Dis. 2012;205 Suppl 3:S355–61. Epub 2012/05/18.

    CAS  PubMed Central  PubMed  Google Scholar 

  22. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92(7):2506–12. Epub 2007/04/26.

    CAS  PubMed Central  PubMed  Google Scholar 

  23. Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173(8):614–22. Epub 2013/03/06.

    CAS  PubMed  Google Scholar 

  24. Freiberg MS, Chang CC, Skanderson M, McGinnis K, Kuller LH, Kraemer KL, et al. The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C. Circ Cardiovasc Qual Outcomes. 2011;4(4):425–32. Epub 2011/06/30.

    PubMed Central  PubMed  Google Scholar 

  25. Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL. Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Quebec's public health insurance database. J Acquir Immune Defic Syndr. 2011;57(3):245–53. Epub 2011/04/19.

    PubMed  Google Scholar 

  26. Obel N, Thomsen HF, Kronborg G, Larsen CS, Hildebrandt PR, Sorensen HT, et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis. 2007;44(12):1625–31. Epub 2007/05/23.

    PubMed  Google Scholar 

  27. Boccara F, Lang S, Meuleman C, Ederhy S, Mary-Krause M, Costagliola D, et al. HIV and coronary heart disease: time for a better understanding. J Am Coll Cardiol. 2013;61(5):511–23. Epub 2013/02/02.

    PubMed  Google Scholar 

  28. WWHOT report: WWHOTwh. 2012. http://www.who.int/gho/publications/world_health_statistics/2012/en/. Accessed 8 Aug 2013

  29. Pearce D, Ani C, Espinosa-Silva Y, Clark R, Fatima K, Rahman M, et al. Comparison of in-hospital mortality from acute myocardial infarction in HIV sero-positive versus sero-negative individuals. Am J Cardiol. 2012;110(8):1078–84. Epub 2012/07/06.

    PubMed  Google Scholar 

  30. Boccara F, Mary-Krause M, Teiger E, Lang S, Lim P, Wahbi K, et al. Acute coronary syndrome in human immunodeficiency virus-infected patients: characteristics and 1 year prognosis. Eur Heart J. 2011;32(1):41–50. Epub 2010/10/23.

    PubMed  Google Scholar 

  31. Lorgis L, Cottenet J, Molins G, Benzenine E, Zeller M, Aube H, et al. Outcomes after acute myocardial infarction in HIV-infected patients: analysis of data from a French nationwide hospital medical information database. Circulation. 2013;127(17):1767–74. Epub 2013/04/02.

    PubMed  Google Scholar 

  32. Klein D, Leyden WA, Xu L, Chao CR, Horberg MA, Towner WJ, et al. Contribution of immunodeficiency to CHD: cohort study of HIV+ and HIV− Kaiser permanent members. Program and abstracts of the 18th conference on retroviruses and opportunitistic infections, Boston, MA; 2011.

    Google Scholar 

  33. Fine DM, Atta MG. Kidney disease in the HIV-infected patient. AIDS Patient Care STDS. 2007;21(11):813–24. Epub 2008/02/05.

    PubMed  Google Scholar 

  34. Crum-Cianflone NF, Weekes J, Bavaro M. Review: thromboses among HIV-infected patients during the highly active antiretroviral therapy era. AIDS Patient Care STDS. 2008;22(10):771–8. Epub 2008/09/12.

    PubMed Central  PubMed  Google Scholar 

  35. Madeddu G, Spanu A, Solinas P, Calia GM, Lovigu C, Chessa F, et al. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging. 2004;48(1):39–48. Epub 2004/06/15.

    PubMed  Google Scholar 

  36. Vescini F, Borderi M, Buffa A, Sinicropi G, Tampellini L, Chiodo F, et al. Bone mass in HIV-infected patients: focus on the role of therapy and sex. J Acquir Immune Defic Syndr. 2003;33(3):405–7. Epub 2003/07/05.

    PubMed  Google Scholar 

  37. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20(17):2165–74. Epub 2006/11/07.

    PubMed  Google Scholar 

  38. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. health care system. J Clin Endocrinol Metab. 2008;93(9):3499–504.

    CAS  PubMed Central  PubMed  Google Scholar 

  39. Young B, Dao CN, Buchacz K, Baker R, Brooks JT. Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000–2006. Clin Infect Dis. 2011;52(8):1061–8. Epub 2011/03/15.

    PubMed  Google Scholar 

  40. Womack JA, Goulet JL, Gibert C, Brandt C, Chang CC, Gulanski B, et al. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One. 2011;6(2):e17217. Epub 2011/03/02.

    CAS  PubMed Central  PubMed  Google Scholar 

  41. Prior J, Burdge D, Maan E, Milner R, Hankins C, Klein M, et al. Fragility fractures and bone mineral density in HIV positive women: a case-control population-based study. Osteoporos Int. 2007;18(10):1345–53. Epub 2007/08/01.

    CAS  PubMed  Google Scholar 

  42. Guerri-Fernandez R, Vestergaard P, Carbonell C, Knobel H, Aviles FF, Castro AS, et al. HIV infection is strongly associated with hip fracture risk, independently of age, gender, and comorbidities: a population-based cohort study. J Bone Miner Res. 2013;28(6):1259–63. Epub 2013/01/31.

    PubMed  Google Scholar 

  43. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med. 2008;148(10):728–36. Epub 2008/05/21.

    PubMed  Google Scholar 

  44. Maki PM, Martin-Thormeyer E. HIV, cognition and women. Neuropsychol Rev. 2009;19(2):204–14. Epub 2009/05/12.

    PubMed Central  PubMed  Google Scholar 

  45. Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry. 2001;158(5):725–30. Epub 2001/05/01.

    CAS  PubMed  Google Scholar 

  46. Siemieniuk RA, Krentz HB, Gill MJ. Intimate partner violence and HIV: a review. Curr HIV AIDS Rep. 2013;10(4):380–9.

    Google Scholar 

  47. Chen JL, Philips KA, Kanouse DE, Collins RL, Miu A. Fertility desires and intentions of HIV-positive men and women. Fam Plan Perspect. 2001;33(4):144–52, 65. Epub 2001/08/11.

    CAS  Google Scholar 

  48. Panozzo L, Battegay M, Friedl A, Vernazza PL. High risk behaviour and fertility desires among heterosexual HIV-positive patients with a serodiscordant partner – two challenging issues. Swiss Med Wkly. 2003;133(7–8):124–7. Epub 2003/03/20.

    PubMed  Google Scholar 

  49. Ross A, Van der Paal L, Lubega R, Mayanja BN, Shafer LA, Whitworth J. HIV-1 disease progression and fertility: the incidence of recognized pregnancy and pregnancy outcome in Uganda. AIDS. 2004;18(5):799–804. Epub 2004/04/13.

    PubMed  Google Scholar 

  50. Sherr L, Barry N. Fatherhood and HIV-positive heterosexual men. HIV Med. 2004;5(4):258–63. Epub 2004/07/09.

    CAS  PubMed  Google Scholar 

  51. Stephenson JM, Griffioen A. The effect of HIV diagnosis on reproductive experience. Study Group for the Medical Research Council Collaborative Study of Women with HIV. AIDS. 1996;10(14):1683–7. Epub 1996/12/01.

    CAS  PubMed  Google Scholar 

  52. Thackway SV, Furner V, Mijch A, Cooper DA, Holland D, Martinez P, et al. Fertility and reproductive choice in women with HIV-1 infection. AIDS. 1997;11(5):663–7. Epub 1997/04/01.

    CAS  PubMed  Google Scholar 

  53. Cooper D, Moodley J, Zweigenthal V, Bekker LG, Shah I, Myer L. Fertility intentions and reproductive health care needs of people living with HIV in Cape Town, South Africa: implications for integrating reproductive health and HIV care services. AIDS Behav. 2009;13 Suppl 1:38–46. Epub 2009/04/04.

    PubMed  Google Scholar 

  54. Nattabi B, Li J, Thompson SC, Orach CG, Earnest J. A systematic review of factors influencing fertility desires and intentions among people living with HIV/AIDS: implications for policy and service delivery. AIDS Behav. 2009;13(5):949–68. Epub 2009/03/31.

    PubMed  Google Scholar 

  55. Hoffman IF, Martinson FE, Powers KA, Chilongozi DA, Msiska ED, Kachipapa EI, et al. The year-long effect of HIV-positive test results on pregnancy intentions, contraceptive use, and pregnancy incidence among Malawian women. J Acquir Immune Defic Syndr. 2008;47(4):477–83. Epub 2008/01/23.

    PubMed  Google Scholar 

  56. Heys J, Kipp W, Jhangri GS, Alibhai A, Rubaale T. Fertility desires and infection with the HIV: results from a survey in rural Uganda. AIDS. 2009;23 Suppl 1:S37–45. Epub 2010/02/02.

    PubMed  Google Scholar 

  57. Desgrées-Du-Loû A, Msellati P, Viho I, Yao A, Yapi D, Kassi P, et al. Contraceptive use, protected sexual intercourse and incidence of pregnancies among African HIV-infected women. DITRAME ANRS 049 Project, Abidjan 1995–2000. Int J STD AIDS. 2002;13(7):462–8.

    PubMed  Google Scholar 

  58. Balkus J, Bosire R, John-Stewart G, Mbori-Ngacha D, Schiff MA, Wamalwa D, et al. High uptake of postpartum hormonal contraception among HIV-1-seropositive women in Kenya. Sex Transm Dis. 2007;34:25–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  59. Polis CB, Gray RH, Lutalo T, Nalugoda F, Kagaayi J, Kigozi G, et al. Trends and correlates of hormonal contraceptive use among HIV-infected women in Rakai, Uganda, 1994–2006. Contraception. 2011;83:549–55.

    PubMed  Google Scholar 

  60. King R, Estey J, Allen S, Kegeles S, Wolf W, Valentine C, et al. A family planning intervention to reduce vertical transmission of HIV in Rwanda. AIDS. 1995;9 Suppl 1:S45–51. Epub 1995/07/01.

    PubMed  Google Scholar 

  61. Rutenberg N, Baek C. Field experiences integrating family planning into programs to prevent mother-to-child transmission of HIV. Stud Fam Plann. 2005;36(3):235–45. Epub 2005/10/08.

    PubMed  Google Scholar 

  62. Grabbe K, Stephenson R, Vwalika B, Ahmed Y, Vwalika C, Chomba E, et al. Knowledge, use, and concerns about contraceptive methods among sero-discordant couples in Rwanda and Zambia. J Womens Health (Larchmt). 2009;18(9):1449–56. Epub 2009/08/28.

    Google Scholar 

  63. Pitter C. PMTCT implementation and the importance of male involvement. Washington, DC: Elizabeth Glaser Pediatric AIDS Foundation; 2010.

    Google Scholar 

  64. Lozano R, Wang H, Foreman KJ, Rajaratnam JK, Naghavi M, Marcus JR, et al. Progress towards millennium development goals 4 and 5 on maternal and child mortality: an updated systematic analysis. Lancet. 2011;378(9797):1139–65. Epub 2011/09/23.

    PubMed  Google Scholar 

  65. van Dillen J, Meguid T, van Roosmalen J. Maternal mortality audit in a hospital in Northern Namibia: the impact of HIV/AIDS. Acta Obstet Gynecol Scand. 2006;85(4):499–500. Epub 2006/04/14.

    PubMed  Google Scholar 

  66. Wandabwa JN, Doyle P, Longo-Mbenza B, Kiondo P, Khainza B, Othieno E, et al. Human immunodeficiency virus and AIDS and other important predictors of maternal mortality in Mulago Hospital Complex Kampala Uganda. BMC Public Health. 2011;11:565. Epub 2011/07/16.

    PubMed Central  PubMed  Google Scholar 

  67. Moran NF, Moodley J. The effect of HIV infection on maternal health and mortality. Int J Gynaecol Obstet. 2012;119 Suppl 1:S26–9. Epub 2012/08/15.

    PubMed  Google Scholar 

  68. Centers for Disease Control and Prevention (CDC). US medical eligibility criteria for contraceptive use. MMWR. 2010;59(RR-4):1–86.

    Google Scholar 

  69. Mirpuri J, Jain L. Issues of prematurity and HIV infection. Clin Perinatol. 2010;37(4):887–905, xi. Epub 2010/11/17.

    PubMed  Google Scholar 

  70. Brocklehurst P, French R. The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-analysis. Br J Obstet Gynaecol. 1998;105(8):836–48. Epub 1998/09/24.

    CAS  PubMed  Google Scholar 

  71. Kuhn L, Semrau K, Ramachandran S, Sinkala M, Scott N, Kasonde P, et al. Mortality and virologic outcomes after access to antiretroviral therapy among a cohort of HIV-infected women who received single-dose nevirapine in Lusaka, Zambia. J Acquir Immune Defic Syndr. 2009;52(1):132–6. Epub 2009/06/10.

    PubMed Central  PubMed  Google Scholar 

  72. Marazzi MC, Palombi L, Nielsen-Saines K, Haswell J, Zimba I, Magid NA, et al. Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes. AIDS. 2011;25(13):1611–8. Epub 2011/06/16.

    CAS  PubMed  Google Scholar 

  73. Parikh L, Timofeev J, Singh J, Sullivan S, Huang CC, Landy HJ, et al. Racial disparities in maternal and neonatal outcomes in HIV-1 positive mothers. Am J Perinatol. 2013. Epub 2013/09/04.

    Google Scholar 

  74. World Health Organization. Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: Programmatic update. Geneva: World Health Organization; 2012.

    Google Scholar 

  75. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Contract No.: Nov 12, 2013.

    Google Scholar 

  76. Panel on Antiretroviral Guidelines for Adults and Adolescents. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. 2013 [updated 7/31/12]. http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Accessed 14 Nov 2013.

  77. UNICEF. Childinfo: monitoring the situation of children and women: statistics by area/HIV/AIDS. 2012.

    Google Scholar 

  78. UN. The millennium development goals report 2012. New York, NY: 2012. Contract No.: 12-24532.

    Google Scholar 

  79. Gray RH, Li X, Kigozi G, Serwadda D, Brahmbhatt H, Wabwire-Mangen F, et al. Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study. Lancet. 2005;366(9492):1182–8. Epub 2005/10/04.

    PubMed  Google Scholar 

  80. Mugo NR, Heffron R, Donnell D, Wald A, Were EO, Rees H, et al. Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples. AIDS. 2011;25(15):1887–95. Epub 2011/07/26.

    PubMed Central  PubMed  Google Scholar 

  81. Morrison CS, Wang J, Van Der Pol B, Padian N, Salata RA, Richardson BA. Pregnancy and the risk of HIV-1 acquisition among women in Uganda and Zimbabwe. AIDS. 2007;21(8):1027–34. Epub 2007/04/26.

    PubMed  Google Scholar 

  82. Stover J, editor. Reducing the costs of effective AIDS control programmes through appropriate targeting of interventions. International AIDS conference, 1996, Vancouver, Canada; 1996.

    Google Scholar 

  83. Peterman TA, Todd KA, Mupanduki I. Opportunities for targeting publicly funded human immunodeficiency virus counseling and testing. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12(1):69–74.

    CAS  PubMed  Google Scholar 

  84. Sweeney C. 1 of 3 Pregnancies unwanted. Popline. 1992;14:1. Epub 1992/01/01.

    CAS  PubMed  Google Scholar 

  85. Kell PD, Barton SE, Boag FC. Incorporating patients' views in planning services for women with HIV infection. Genitourin Med. 1992;68(4):233–4.

    CAS  PubMed Central  PubMed  Google Scholar 

  86. McCarthy GA, Cockell AP, Kell PD, Beevor AS, Boag FC. A women-only clinic for HIV, genitourinary medicine and substance misuse. Genitourin Med. 1992;68(6):386–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  87. Carlin EM, Russell JM, Sibley K, Boag FC. Evaluating a designated family planning clinic within a genitourinary medicine clinic [see comments]. Genitourin Med. 1995;71(2):106–8.

    CAS  PubMed Central  PubMed  Google Scholar 

  88. Cates Jr W, Stone K. Family planning, sexually transmitted disease, and contraceptive choice: a literature update. Part II. Fam Plann Perspect. 1992;24(3):122–8.

    PubMed  Google Scholar 

  89. Daley D. Reproductive health and AIDS-related services for women: how well are they integrated? Fam Plann Perspect. 1994;26(6):264–9. Epub 1994/11/01.

    CAS  PubMed  Google Scholar 

  90. Becker J, Ureno M. How HIV has helped family planning: sexuality, the essential link. International conference on AIDS, Vancover, BC, 7–12 Jul 1996

    Google Scholar 

  91. Chandhok K, Sankaran S, Peters S, Mathews G, Manoharan S, Thomas S, editors. Developing comprehensive intervention programs for women in the reproductive age group. International AIDS conference, Vancouver, BC, Canada; 1996.

    Google Scholar 

  92. Hamid S, Stephenson R. Provider and health facility influences on contraceptive adoption in urban Pakistan. Int Fam Plan Perspect. 2006;32(2):71–8. Epub 2006/07/14.

    PubMed  Google Scholar 

  93. Badell ML, Lathrop E, Haddad LB, Goedken P, Nguyen ML, Cwiak CA. Reproductive health care needs and desires in a cohort of HIV-positive women. Infect Dis Obstet Gynecol. 2012;2012:107878. Epub 2012/07/05.

    PubMed Central  PubMed  Google Scholar 

  94. Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR 2010;59(RR-12). Epub 17 Dec 2010.

    Google Scholar 

  95. ACOG Practice Bulletin No. 117: gynecologic care for women with human immunodeficiency virus. Obstet Gynecol. 2010;116(6):1492–509. Epub 26 Nov 2010.

    Google Scholar 

  96. Zuckerman RA, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, Zuniga R, et al. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis. 2007;196(10):1500–8. Epub 2007/11/17.

    CAS  PubMed  Google Scholar 

  97. Baeten JM, Strick LB, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, et al. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis. 2008;198(12):1804–8. Epub 2008/10/22.

    CAS  PubMed Central  PubMed  Google Scholar 

  98. Dunne EF, Whitehead S, Sternberg M, Thepamnuay S, Leelawiwat W, McNicholl JM, et al. Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand. J Acquir Immune Defic Syndr. 2008;49(1):77–83. Epub 2008/08/01.

    CAS  PubMed  Google Scholar 

  99. Celum C, Wald A, Lingappa JR, Magaret AS, Wang RS, Mugo N, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med. 2010;362(5):427–39. Epub 2010/01/22.

    CAS  PubMed Central  PubMed  Google Scholar 

  100. Mujugira A, Magaret AS, Celum C, Baeten JM, Lingappa JR, Morrow RA, et al. Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial. J Infect Dis. 2013;208(9):1366–74. Epub 2013/08/01.

    CAS  PubMed  Google Scholar 

  101. Kojic E, Cu-Uvin S. Safety of and immune response to the human papillomavirus (HPV) vaccine in HIV-infected women. National Library of Medicine; 2013. http://clinicaltrials.gov/ct2/show/NCT00604175. Accessed 14 Nov 2013

  102. Kahn J, Squires K. Impact of an HPV vaccine in HIV-infected young women. National Library of Medicine; 2013. http://clinicaltrials.gov/ct2/show/NCT00604175. Accessed 14 Nov 2013

  103. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010 MMWR recommendations and reports. MMWR. 2010;59(RR-12):1–110. Epub 2010/12/17.

    PubMed  Google Scholar 

  104. Conde DM, Silva ET, Amaral WN, Finotti MF, Ferreira RG, Costa-Paiva L, et al. HIV, reproductive aging, and health implications in women: a literature review. Menopause. 2009;16(1):199–213. Epub 2008/09/19.

    PubMed  Google Scholar 

  105. Kanapathipillai R, Hickey M, Giles M. Human immunodeficiency virus and menopause. Menopause. 2013;20(9):983–90. Epub 2013/03/28.

    PubMed  Google Scholar 

  106. Centers for Disease Control. U.S. medical eligibility criteria for contraceptive use, 2010. MMWR recommendations and reports: morbidity and mortality weekly report recommendations and reports. MMWR. 2010;59(RR-4):1–86. Epub 2010/06/19.

    Google Scholar 

  107. CDC. Update to CDC's US medical eligibility criteria for contraceptive use, 2010: revised recommendations for the use of hormonal contraception among women at high risk for HIV infection or infected with HIV. MMWR. 2012;61(24):449–52. Epub 2012/06/22.

    Google Scholar 

  108. Sivin I, Stern J, Coutinho E, Mattos CE, el Mahgoub S, Diaz S, et al. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the Copper T380 Ag IUDS. Contraception. 1991;44(5):473–80. Epub 1991/11/01.

    CAS  PubMed  Google Scholar 

  109. Trussell J. Contraceptive efficacy. Arch Dermatol. 1995;131(9):1064–8. Epub 1995/09/01.

    CAS  PubMed  Google Scholar 

  110. Hatcher RA, Trussell J, Stewart FH, Nelson AL, Cates W, Guest F, et al. Contraceptive technology, 20th rev ed. New York: Ardent Media, Inc.; 2011. xxviii, 871 p., [7] p. of plates p.

    Google Scholar 

  111. Toivonen J, Luukkainen T, Allonen H. Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years' comparative experience of levonorgestrel- and copper-releasing intrauterine devices. Obstet Gynecol. 1991;77(2):261–4. Epub 1991/02/01.

    CAS  PubMed  Google Scholar 

  112. Long-term reversible contraception. Twelve years of experience with the TCu380A and TCu220C. Contraception. 1997;56(6):341–52. Epub 1998/03/12.

    Google Scholar 

  113. Hatcher R, Trussell J, Nelson A, Cates W, Stewart F, Kowel D. Contraceptive technology. 20th ed. New York: Ardent Media; 2011.

    Google Scholar 

  114. Leticee N, Viard JP, Yamgnane A, Karmochkine M, Benachi A. Contraceptive failure of etonogestrel implant in patients treated with antiretrovirals including efavirenz. Contraception. 2012;85(4):425–7. Epub 2011/11/01.

    CAS  PubMed  Google Scholar 

  115. CDC. U.S. selected practice recommendations for contraceptive use, 2013: adapted from the World Health Organization selected practice recommendations for contraceptive use, 2nd ed. MMWR Centers Dis Control. 2013;62(RR-05):1–60. Epub 2013/06/21.

    Google Scholar 

  116. Trussell J, Sturgen K, Strickler J, Dominik R. Comparative contraceptive efficacy of the female condom and other barrier methods. Fam Plann Perspect. 1994;26(2):66–72. Epub 1994/03/01.

    CAS  PubMed  Google Scholar 

  117. Gallo MF, Kilbourne-Brook M, Coffey PS. A review of the effectiveness and acceptability of the female condom for dual protection. Sex Health. 2012;9(1):18–26. Epub 2012/02/22.

    PubMed  Google Scholar 

  118. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 2002;360(9338):971–7. Epub 2002/10/18.

    PubMed  Google Scholar 

  119. Gupta SK. Nutan. Clinical use of vaginal or rectally applied microbicides in patients suffering from HIV/AIDS. HIV. HIV AIDS (Auckl). 2013;5:295–307.

    Google Scholar 

  120. Padian NS, van der Straten A, Ramjee G, Chipato T, de Bruyn G, Blanchard K, et al. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet. 2007;370(9583):251–61. Epub 2007/07/17.

    PubMed Central  PubMed  Google Scholar 

  121. Brache V, Cochon L, Deniaud M, Croxatto HB. Ulipristal acetate prevents ovulation more effectively than levonorgestrel: analysis of pooled data from three randomized trials of emergency contraception regimens. Contraception. 2013;88(5):611–8. Epub 2013/07/03.

    CAS  PubMed  Google Scholar 

  122. German P, Wang M, Warren D, Kearney B, editors. Pharmacokinetic interaction between norgestimate/ethinyl estradiol and EVG/COBI/FTC/TDF single tablet regimen. 12th International workshop on clinical pharmacology of HIV therapy, Miami, FL, Apr 2011.

    Google Scholar 

  123. Carten M, Kiser J, Kwara A, Ma Whinney S, S. C-U, editors. Pharmacokinetic (PK) interactions between the hormonal emergency contraception Plan B (levonorgestrel) and efavirenz (EFV). 17th Conference on retroviruses and opportunistic infection, San Francisco, Feb 2010

    Google Scholar 

  124. Robinson JA, Jamshidi R, Burke AE. Contraception for the HIV-positive woman: a review of interactions between hormonal contraception and antiretroviral therapy. Infect Dis Obstet Gynecol. 2012;2012:890160. Epub 2012/08/29.

    PubMed Central  PubMed  Google Scholar 

  125. Adolescents PoAGfAa. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; 2013. http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Accessed 2 Nov 2013.

  126. Centers for Disease Control and Prevention (CDC). Update to CDC's US medical eligibility criteria for contraceptive use, 2010: revised recommendations for the use of hormonal contraception among women at high risk for HIV infection or infected with HIV. MMWR. 2012;61(24):449–52. Epub 22 Jun 2012.

    Google Scholar 

  127. Nanda K, Amaral E, Hays M, Viscola MA, Mehta N, Bahamondes L. Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy. Fertil Steril. 2008;90(4):965–71. Epub 2007/09/21.

    CAS  PubMed  Google Scholar 

  128. Watts DH, Park JG, Cohn SE, Yu S, Hitti J, Stek A, et al. Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093. Contraception. 2008;77(2):84–90. Epub 2008/01/30.

    CAS  PubMed Central  PubMed  Google Scholar 

  129. Cohn SE, Park JG, Watts DH, Stek A, Hitti J, Clax PA, et al. Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions. Clin Pharmacol Therapy. 2007;81(2):222–7. Epub 2006/12/29.

    CAS  Google Scholar 

  130. Vogler MA, Patterson K, Kamemoto L, Park JG, Watts H, Aweeka F, et al. Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188. J Acquir Immune Defic Syndr. 2010;55(4):473–82. Epub 2010/09/16.

    CAS  PubMed  Google Scholar 

  131. Kearney B, Isaacson E, Sayre J, Cheng A, editors. Tenofovir DF and oral contraceptives: lack of a pharmacokinetic drug interaction. 43rd Interscience conference on antimicrobial agents and chemotherapy, Chicago, IL; Washington, DC, 14–17 Sep 2003.

    Google Scholar 

  132. Aweeka FT, Rosenkranz SL, Segal Y, Coombs RW, Bardeguez A, Thevanayagam L, et al. The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine. AIDS. 2006;20(14):1833–41. Epub 2006/09/07.

    CAS  PubMed  Google Scholar 

  133. Joshi A, Fiske W, Benedek I, White SJ, Joseph JL, Kornhauser DM. Lack of a pharmacokinetic interaction between efavirenz (DMP 266) and ethinyl estradiol in healthy female volunteers. 5th Conference on retroviruses and opportunistic infections, Chicago, IL, 1–5 Feb 1998.

    Google Scholar 

  134. Sevinsky H, Eley T, He B, et al. Effect of efavirenz on the pharmacokinetics of ethinyl estradiol and norgestimate in healthy female subjects [Abstract A958]. In: Program and abstracts of the 48th interscience conference on antimicrobial agents and chemotherapy, Washington, DC, 25–28 Oct 2008. Washington, DC: American Society for Microbiology; 2008.

    Google Scholar 

  135. Scholler-Gyure M, Debroye C, Aharchi F, et al. No clinically relevant effect of TMC125 on the pharmacokinetics of oral contraceptives. 8th International congress on drug therapy in HIV infection, Glasgow, 12–16 Nov 2006.

    Google Scholar 

  136. Mildvan D, Yarrish R, Marshak A, Hutman HW, McDonough M, Lamson M, et al. Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women. J Acquir Immune Defic Syndr. 2002;29(5):471–7. Epub 2002/05/01.

    CAS  PubMed  Google Scholar 

  137. Tibotec Therapeutics Inc. Edurant [package insert]. Raritan, NJ; 2011.

    Google Scholar 

  138. Bristol-Meyers Squibb. Reyataz (atazanavir) package label. 2010.

    Google Scholar 

  139. Sekar V, Lefebvre E, Seal S. Pharmacokinetic interaction between nevirapine and ethinyl estradiol, norethindrone, and TMC114, a new protease inhibitor [Abstract A-368]. San Francisco, CA: American Society for Microbiology, 27–30 Sep 2006. Report No.; 2006

    Google Scholar 

  140. Glaxo Smith Kline. Prescription medicines. Lexiva (fosamprenavir calcium). 2009.

    Google Scholar 

  141. Glaxo Smith Kline. Study APV10020. A phase I, open label, two period, single-sequence, drug–drug interaction study comparing steady-state plasma ethinyl estradiol and norethisterone pharmacokinetics following administration of brevinor for 21 days with and without fosamprenavir 700 mg twice daily (BID) and ritonavir 100 mg (BID) for 21 days in healthy adult female subjects. 2009.

    Google Scholar 

  142. Abbott Laboratories. Lopinavir and ritonavir prescribing information. North Chicago, IL: Abbott Laboratories; 2009.

    Google Scholar 

  143. Boehringer Ingelheim Pharmaceuticals I. Aptivus [package insert]. Ridgefield, CT: Nov 2005. Report No.; 2005.

    Google Scholar 

  144. Food and Drug Administration. Highlights of prescribing information. Aptivus (Tipranavir) Capsules. USFDA; 2009.

    Google Scholar 

  145. Glaxo Wellcome Inc. Agenerase [package insert]. Research Triangle Park, NC; 2004.

    Google Scholar 

  146. Agouron Pharmaceuticals. Viracept (Nelfinavir mesylate) prescribing information. San Diego, CA: Agouron Pharmaceuticals; 2008.

    Google Scholar 

  147. Anderson MS, Hanley WD, Moreau AR, Jin B, Bieberdorf FA, Kost JT, et al. Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women. Br J Clin Pharmacol. 2011;71(4):616–20. Epub 2011/03/15.

    CAS  PubMed Central  PubMed  Google Scholar 

  148. Baeten JM, Benki S, Chohan V, Lavreys L, McClelland RS, Mandaliya K, et al. Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. AIDS. 2007;21(13):1771–7. Epub 2007/08/11.

    PubMed  Google Scholar 

  149. Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis. 2012;12(1):19–26. Epub 2011/10/07.

    PubMed Central  PubMed  Google Scholar 

  150. Hel Z, Stringer E, Mestecky J. Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection. Endocr Rev. 2010;31(1):79–97. Epub 2009/11/12.

    CAS  PubMed Central  PubMed  Google Scholar 

  151. Polis CB, Curtis KM. Use of hormonal contraceptives and HIV acquisition in women: a systematic review of the epidemiological evidence. Lancet Infect Dis. 2013;13(9):797–808. Epub 2013/07/23.

    PubMed  Google Scholar 

  152. Stringer EM, Kaseba C, Levy J, Sinkala M, Goldenberg RL, Chi BH, et al. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol. 2007;197(2):144e1-8. Epub 2007/08/11.

    Google Scholar 

  153. Phillips SJ, Curtis KM, Polis CB. Effect of hormonal contraceptive methods on HIV disease progression: a systematic review. AIDS. 2013;27(5):787–94. Epub 2012/11/09.

    CAS  PubMed  Google Scholar 

  154. Cejtin HE, Jacobson L, Springer G, Watts DH, Levine A, Greenblatt R, et al. Effect of hormonal contraceptive use on plasma HIV-1-RNA levels among HIV-infected women. AIDS. 2003;17(11):1702–4. Epub 2003/07/11.

    PubMed  Google Scholar 

  155. Richardson BA, Otieno PA, Mbori-Ngacha D, Overbaugh J, Farquhar C, John-Stewart GC. Hormonal contraception and HIV-1 disease progression among postpartum Kenyan women. AIDS. 2007;21(6):749–53. Epub 2007/04/07.

    PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA, USA

    Lisa B. Haddad M.D., M.S., M.P.H. & Jessica Tarleton M.D., M.P.H.

  2. Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA

    Anandi N. Sheth M.D. & Ighovwerha Ofotokun M.D., M.Sc.

Authors
  1. Lisa B. Haddad M.D., M.S., M.P.H.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jessica Tarleton M.D., M.P.H.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anandi N. Sheth M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ighovwerha Ofotokun M.D., M.Sc.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lisa B. Haddad M.D., M.S., M.P.H. .

Editor information

Editors and Affiliations

  1. Department of Obstetrics and Gynecology, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA

    Rebecca H. Allen

  2. Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, Georgia, USA

    Carrie A. Cwiak

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Haddad, L.B., Tarleton, J., Sheth, A.N., Ofotokun, I. (2014). Contraception for Women Living with HIV. In: Allen, R., Cwiak, C. (eds) Contraception for the Medically Challenging Patient. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1233-9_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1233-9_6

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-1232-2

  • Online ISBN: 978-1-4939-1233-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation